Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.47 |
| ▸ | HTR3B | O95264 | 4/20 | 0.47 |
| ▸ | HTR3A | P46098 | 4/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13914877 | 0.88 | HTR3A (0.49) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL601384 | 0.88 | HTR3A (0.49) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL602081 | 0.85 | SMYD3 (0.58) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL29086776 | 0.83 | RAB9A (0.51) | KMT2A | |
| SCHEMBL30912935 | 0.83 | RAB9A (0.51) | KMT2A | |
| SCHEMBL602548 | 0.83 | HRH4 (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL29086887 | 0.82 | RAB9A (0.53) | MEN1KMT2A | |
| SCHEMBL30912932 | 0.82 | RAB9A (0.53) | MEN1KMT2A | |
| SCHEMBL605257 | 0.80 | MEN1 (0.46) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL605537 | 0.78 | HTR3E (0.53) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504426-B2 | Heterocyclic compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-17 | — | — | US | claimed |
| US-20120039913-A1 | Selective Histamine H4 Receptor Antagonists for the Treatment of Vestibular Disorders | INSERM (institut National de la Sante de la Recher Medicale) (FR) | 2012-02-16 | — | — | US | disclosed |
| US-7504426-B2 | Heterocyclic compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-17 | — | — | US | disclosed |
| US-7504426-B2 | Heterocyclic compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-17 | — | — | US | disclosed |